Compare ZCMD & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZCMD | COCH |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Blank Checks |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 51.0M |
| IPO Year | 2019 | 2021 |
| Metric | ZCMD | COCH |
|---|---|---|
| Price | $0.76 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.2M | 40.6K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.02 | $0.36 |
| 52 Week High | $11.96 | $1.89 |
| Indicator | ZCMD | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 48.51 |
| Support Level | $0.71 | $0.63 |
| Resistance Level | $0.79 | $0.74 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.20 | 35.90 |
ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.